RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 1

Registered title, quoted from ClinicalTrials.gov

A Study of FZ-AD005 in Patients With Advanced Solid Tumors

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 3 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 3

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  2. Study siteShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page
  3. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06424665, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients have histological or cytological diagnosis with advanced solid tumors ( especially SCLC or LCNEC);

    Inclusion criterion 3

  3. Patients of child bearing potential must agree to take contraception during the study and for 6 months after the last day of treatment.

    Inclusion criterion 8

    Patients who have had previous treatment with any anti-DLL3 antibody;

    Exclusion criterion 1

  4. Eastern Cancer Cooperative Group (ECOG) performance status 0-1;

    Inclusion criterion 7

  5. Have measurable lesions defined in RECIST v. 1.1;

    Inclusion criterion 5

  6. Have had other malignant tumors in the past 5 years;

    Exclusion criterion 2

  7. Female patients who are breastfeeding or pregnant;

    Exclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06424665, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients able to give written informed consent;
  • Age ≥ 18 and ≤ 75 years old, male or female;
  • Patients have histological or cytological diagnosis with advanced solid tumors ( especially SCLC or LCNEC);
  • Willingness to provide tumor tissue for testing ;
  • Have measurable lesions defined in RECIST v. 1.1;
  • Expected survival ≥ 3 months;
  • Eastern Cancer Cooperative Group (ECOG) performance status 0-1;
  • Patients of child bearing potential must agree to take contraception during the study and for 6 months after the last day of treatment.

Exclusion Criteria:

  • Patients who have had previous treatment with any anti-DLL3 antibody;
  • Have had other malignant tumors in the past 5 years;
  • Patients who are receiving other anti-tumor treatments within 4 weeks prior to the first dose;
  • Have active CNS (central nervous system) metastasis;
  • Had undergone major surgery or severe trauma within 4 weeks prior to the first dose;
  • Had undergone systemic high-dose steroids within 2 weeks of initiation of study treatment;
  • Patients have psychiatric history;
  • Female patients who are breastfeeding or pregnant;
  • Other reasons that researchers believe are inappropriate to participate in this study.

Quoted from ClinicalTrials.gov, NCT06424665, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06424665, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06424665